Active Ingredient History
Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). It is an oral VEGF receptor tyrosine kinase inhibitor. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Bile Duct Neoplasms (Phase 1/Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 3)
Cholangiocarcinoma (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Epidermal Growth Factor (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 1/Phase 2)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
Glioblastoma (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Neoplasms ()
Neuroendocrine Tumors (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacology (Phase 1)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue